Search Results

You are looking at 1 - 8 of 8 items for :

  • "polycythaemia vera" x
  • User-accessible content x
Clear All
Orvosi Hetilap
Authors: Péter Dombi, Árpád Illés, Judit Demeter, Lajos Homor, Zsófia Simon, Ádám Kellner, Éva Karádi, Erika Valasinyószki, Miklós Udvardy, and Miklós Egyed

neoplasms. Eur J Haematol. 2015; 95: 270–279. 3 Tefferi A. Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management. Am J

Open access
Orvosi Hetilap
Authors: Péter Dombi, Árpád Illés, Judit Demeter, Lajos Homor, Zsófia Simon, Miklós Udvardy, and Miklós Egyed

. Med., 2013, 369 (25), 2379–2390. 3 Moulard, O., Mehta, J., Fryzek, J., et al.: Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European

Open access
Orvosi Hetilap
Authors: Tünde Krähling, Katalin Balassa, Nóra Meggyesi, András Bors, Judit Csomor, Árpád Bátai, Gabriella Halm, Miklós Egyed, Sándor Fekete, Péter Reményi, Tamás Masszi, Attila Tordai, and Hajnalka Andrikovics

constitutive signalling causes polycythaemia vera. Nature, 2005, 434 (7037), 1144–1148. Kralovics, R., Passamonti, F., Buser, A. S., et al.: A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J

Open access
Orvosi Hetilap
Authors: Péter Dombi, Árpád Illés, Judit Demeter, Lajos Homor, Zsófia Simon, Miklós Udvardy, Éva Karádi, Ádám Kellner, and Miklós Egyed

, A., Barbui, T.: Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. Am. J. Hematol., 2015, 90 (2), 162–173. 8

Open access

–2720. Marchetti, M., Castoldi, E., Spronk, H. M., et al.: Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. Blood, 2008, 112 (10), 4061–4068. Panova

Open access

ONE 2020; 15: e0226879. 25 Gisslinger H, Klade C, Georgiev P, et al. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera

Open access

myelofibrosis, essential thrombocythaemia and polycythaemia vera in the European Union. Eur J Haematol. 2014; 92: 289–297. 37 Jakó J, Szerafin L

Open access
Interventional Medicine and Applied Science
Authors: Adam Hatzidakis, Nikolaos Galanakis, Elias Kehagias, Dimitrios Samonakis, Mairi Koulentaki, Erminia Matrella, and Dimitrios Tsetis

clinical presentation, BCS can be classified as fulminant, acute, subacute, or chronic [ 2 ]. The most common underlying disorders in patients with BCS are hematologic abnormalities, such as polycythemia vera and essential thrombocytosis [ 3 ]. In Western

Open access